{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:37:18Z","timestamp":1780321038469,"version":"3.54.1"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet Med"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This analysis assessed the cost\u2010effectiveness of insulin glargine 300\u2009units\/mL (Gla\u2010300) versus insulin glargine 100\u2009units\/mL (Gla\u2010100) in insulin\u2010na\u00efve adults with type 2 diabetes (T2D) inadequately controlled with oral antidiabetic drugs (OADs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Costs and outcomes for Gla\u2010300 versus Gla\u2010100 from a US healthcare payer perspective were assessed using the BRAVO diabetes model. Baseline clinical data were derived from EDITION\u20103, a 12\u2010month randomized controlled trial comparing Gla\u2010300 with Gla\u2010100 in insulin\u2010na\u00efve adults with inadequately controlled T2D on OADs. Treatment costs were calculated based on doses observed in EDITION\u20103 and 2020 US net prices, while costs for complications were based on published literature. Lifetime costs ($US) and quality\u2010adjusted life\u2010years (QALYs) were predicted and used to calculate incremental cost\u2010effectiveness ratio (ICER) estimates; extensive scenario and sensitivity analyses were conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Lifetime medical costs were estimated to be $353,441 and $352,858 for individuals receiving Gla\u2010300 and Gla\u2010100 respectively; insulin costs were $52,613 and $50,818. Gla\u2010300 was associated with a gain of 8.97 QALYs and 21.12 life\u2010years, while Gla\u2010100 was associated with a gain of 8.89 QALYs and 21.07 life\u2010years. This resulted in an ICER of $7522\/QALY gained for Gla\u2010300 versus Gla\u2010100. Thus, Gla\u2010300 was cost\u2010effective versus Gla\u2010100 based on a willingness\u2010to\u2010pay threshold of $50,000\/QALY. Compared with Gla\u2010100, Gla\u2010300 provided a net monetary benefit of $3290. Scenario and sensitivity analyses confirmed the robustness of the base case.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Gla\u2010300 may be a cost\u2010effective treatment option versus Gla\u2010100 over a lifetime horizon for insulin\u2010na\u00efve people in the United States with T2D inadequately controlled on OADs.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dme.15303","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T12:35:56Z","timestamp":1710246956000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An exploratory analysis of the cost\u2010effectiveness of insulin glargine 300\u2009units\/<scp>mL<\/scp> versus insulin glargine 100\u2009units\/<scp>mL<\/scp> over a lifetime horizon using the <scp>BRAVO<\/scp> diabetes model"],"prefix":"10.1111","volume":"41","author":[{"given":"Hui","family":"Shao","sequence":"first","affiliation":[{"name":"Hubert Department of Global Health Emory Rollins School of Public Health  Atlanta Georgia USA"},{"name":"Department of Pharmaceutical Outcomes and Policy University of Florida College of Pharmacy  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizheng","family":"Shi","sequence":"additional","affiliation":[{"name":"School of Public Health and Tropical Medicine Tulane University  New Orleans Louisiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Fonseca","sequence":"additional","affiliation":[{"name":"School of Medicine Tulane University  New Orleans Louisiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Jabbar Omar","family":"Alsaleh","sequence":"additional","affiliation":[{"name":"Sanofi  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder","family":"Gill","sequence":"additional","affiliation":[{"name":"Sanofi  Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Sanofi  Reading UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Centers for Disease Control and Prevention.National diabetes statistics report website. Accessed November 10 2022https:\/\/www.cdc.gov\/diabetes\/basics\/type2.html.2021"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0787-8"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0007"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.3.385"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0939"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2258"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1710"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03605.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12438"},{"key":"e_1_2_9_11_1","unstructured":"Sanofi\u2010Aventis.Prescribing information for Toujeo\u00ae(insulin glargine injection) U\u2010300. Accessed November 10 2022https:\/\/products.sanofi.us\/toujeo\/toujeo.pdf"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2017.04.007"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802743"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108316"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.08.007"},{"key":"e_1_2_9_16_1","unstructured":"Agency for Healthcare Research and Quality.Medical expenditure panel survey. Accessed November 10 2022https:\/\/www.meps.ahrq.gov\/mepsweb"},{"key":"e_1_2_9_17_1","unstructured":"Sanofi.Data on file.2022."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0662-1"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.7705"},{"key":"e_1_2_9_20_1","unstructured":"Institute for Clinical and Economic Review.Unsupported price increase report \u2013 2020 assessment. Accessed November 26 2021https:\/\/icer.org\/assessment\/unsupported\u2010price\u2010increase\u20102020\/"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.4843"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0381"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00775-8"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2151"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0405-5"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.467"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.07.301"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0465"},{"key":"e_1_2_9_29_1","unstructured":"Institute for Clinical and Economic Review.Tirzepatide for type 2 diabetes: draft background and scope.2021. Accessed October 14 2021https:\/\/icer.org\/wp\u2010content\/uploads\/2021\/06\/ICER_Type\u20102\u2010Diabetes_Draft\u2010Scope_063021.pdf"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2048"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1178126"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.15303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T09:16:54Z","timestamp":1713259014000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.15303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/dme.15303"],"URL":"https:\/\/doi.org\/10.1111\/dme.15303","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"2023-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e15303"}}